Eli Lilly - Biotech Market Share Report

Company: Eli Lilly
2007 Sales: $3.9 billion
Market share: 5.2%
CAGR: 4.7%

What they have: Eli Lilly has only one biologic blockbuster, despite the fact that it ranks fifth in overall biologic sales. Humalog, a Type 1 and 2 diabetes treatment, brought in $1.5 billion in sales in 2007. The company's big sellers include Forteo, a synthetic form of the natural occurring hormone that treats osteoporosis in men and women, and Xigris, a treatment for sepsis. About 25 percent of Lilly's 2007 sales came from biotech medicines.

What to look for: Biotech molecules also represent approximately one-third of the Lilly's current pipeline, including potential treatments targeting Alzheimer's disease, cancer and diabetes, according to a recent release. Lilly is working with MacroGenics to develop teplizumab, a humanized anti-CD3 monoclonal antibody for Type 1 diabetes which is in Phase III trials. The company is also partnered with Canadian biotech BioMS to develop dirucotide, a multiple sclerosis treatment. Many of the company's other biotech drugs are in Phase I or II trials